Is CyberArk The Next Big Cybersecurity Stock?
CyberArk Software (NASDAQ: CYBR) recently reported phenomenal quarter numbers, passing…
Buy
64
MASS Quote, Financials, Valuation and Earnings
Last price:
$4.30
Seasonality move
:
-10.27%
Day range:
$3.93 - $4.75
52-week range:
$1.81 - $7.56
Dividend yield:
0%
P/E ratio:
--
P/S ratio:
2.62x
P/B ratio:
1.42x
Volume:
1.3M
Avg. volume:
5.4M
1-year change:
-31.7%
Market cap:
$162.2M
Revenue:
$59.6M
EPS (TTM):
-$2.10
Analysts' Opinion
-
Consensus Rating908 Devices has received a consensus rating of Buy. The company's average rating is a Buy based on 3 Buy ratings, 1 Hold rating, and 0 Sell ratings.
-
Price Target UpsideAccording to analysts' consensus price target of $6.00, 908 Devices has an estimated upside of 19.83% from its current price of $4.59.
-
Price Target DownsideAccording to analysts, the lowest downside price target is $6.00 representing 100% downside risk from its current price of $4.59.
Fair Value
-
According to the consensus of 4 analysts, 908 Devices has 19.83% upside to fair value with a price target of $6.00 per share.
MASS vs. S&P 500
-
Over the past 5 trading days, 908 Devices has overperformed the S&P 500 by 49.96% suggesting its relative strength compared to the major market average is strong at this time.
Share Buyback
-
908 Devices does have a share repurchase program in place at this time. The scale of a buyback program can materially affect share price and usually results in a higher earnings per share, all else being equal, when the share count drops.
Revenue Growth
-
908 Devices has grown year-over-year revenues for 5 quarters straight. In the most recent quarter 908 Devices reported revenues of $18.8M.
Earnings Growth
-
908 Devices has grown year-over-year earnings for 0 quarters straight. In the most recent quarter 908 Devices reported earnings per share of -$0.56.
Enterprise value:
92.6M
EV / Invested capital:
0.81x
Price / LTM sales:
2.62x
EV / EBIT:
--
EV / Revenue:
1.55x
PEG ratio (5yr expected):
-0.03x
EV / Free cash flow:
-3.00x
Price / Operating cash flow:
--
Enterprise value / EBITDA:
--
Gross Profit (TTM):
$29.9M
Return On Assets:
-38.44%
Net Income Margin (TTM):
-121.09%
Return On Equity:
-49.84%
Return On Invested Capital:
-49.84%
Operating Margin:
-59.47%
| Trailing 12 Months | Fiscal Quarters | |||||
|---|---|---|---|---|---|---|
| Period Ending | 2022-12-31 | 2023-12-31 | 2024-12-31 | 2023-12-31 | 2024-12-31 | |
| Income Statement | ||||||
| Revenue | $46.9M | $50.2M | $59.6M | $14.4M | $18.8M | |
| Gross Profit | $26M | $25.3M | $29.9M | $7.3M | $9.1M | |
| Operating Income | -$35.4M | -$42.9M | -$49.3M | -$9.9M | -$11.2M | |
| EBITDA | -$31.8M | -$35.4M | -$67.8M | -$7M | -$18.1M | |
| Diluted EPS | -$1.07 | -$1.13 | -$2.10 | -$0.23 | -$0.56 | |
| Period Ending | 2020-12-31 | 2021-12-31 | 2022-12-31 | 2023-12-31 | 2024-12-31 | |
|---|---|---|---|---|---|---|
| Balance Sheet | ||||||
| Current Assets | $171M | $252.9M | $215.6M | $173.8M | $103.1M | |
| Total Assets | $178.8M | $260.9M | $242.6M | $203M | $159.5M | |
| Current Liabilities | $10.8M | $14.8M | $19.2M | $22.5M | $25.1M | |
| Total Liabilities | $39.8M | $46.3M | $52M | $37.5M | $44.9M | |
| Total Equity | $139M | $214.6M | $190.6M | $165.5M | $114.6M | |
| Total Debt | $14.8M | $15M | $15M | -- | -- | |
| Trailing 12 Months | Fiscal Quarters | |||||
|---|---|---|---|---|---|---|
| Period Ending | 2022-12-31 | 2023-12-31 | 2024-12-31 | 2023-12-31 | 2024-12-31 | |
| Cash Flow Statement | ||||||
| Cash Flow Operations | -$20.9M | -$25.1M | -$30.2M | -$1.9M | -$2.2M | |
| Cash From Investing | -$15.8M | -$26.4M | -$46.3M | $4.6M | $780K | |
| Cash From Financing | $1.2M | -$15.9M | -$376K | $95K | $529K | |
| Free Cash Flow | -$23M | -$27.1M | -$30.8M | -$2.3M | -$2.4M | |
MASS
Sector
Market Cap
$162.2M
$91.6M
Price % of 52-Week High
60.71%
60%
Dividend Yield
0%
0%
Shareholder Yield
-1.48%
0.82%
1-Year Price Total Return
-31.7%
-15.91%
Beta (5-Year)
--
0.910
Dividend yield:
0%
Annualized payout:
$0.00
Payout ratio:
--
Growth streak:
0 years
SEE THE 1% OF STOCKS YOU NEED TO OWN FOR MASSIVE RETURNS
GET BETTER TRADE IDEAS
Technicals
8-day SMA
Buy
Level
$3.76
200-day SMA
Buy
Level
$3.69
Bollinger Bands (100)
Buy
Level
2.11 - 3.33
Chaikin Money Flow
Buy
Level
78.1M
20-day SMA
Buy
Level
$3.05
Relative Strength Index (RSI14)
Buy
Level
66.74
ADX Line
Buy
Level
33.57
Williams %R
Sell
Level
-7.2917
50-day SMA
Buy
Level
$2.69
MACD (12, 26)
Buy
Level
0.46
25-day Aroon Oscillator
Buy
Level
28
On Balance Volume
Neutral
Level
113.7M
Financial Scores
Sell
Altman Z-Score
(Annual)
Level (-1.6392)
Sell
CA Score
(Annual)
Level (-0.8874)
--
Beneish M-Score
(Annual)
Level (--)
Sell
Momentum Score
Level (1)
Sell
Ohlson Score
Level (2.8653)
Buy
Piotroski F Score
(Annual)
Level (4)
Sell
Quality Ratio Score
Level (3)
Buy
Fundamental Score
Level (5)
Revenue Forecast
Earnings per Share Forecast
Company Profile
908 Devices Inc manufactures medical devices. It has developed a suite of purpose-built handheld and desktop mass spectrometry, or Mass Spec, devices for the point-of-need. Mass Spec devices are used at the point-of-need to interrogate unknown and invisible materials and provide quick, actionable answers to directly address some of the critical problems in life sciences research, bioprocessing, industrial biotech, forensics, and adjacent markets. The company geographically derives maximum revenue from United States, and also has its presence in Europe, Middle East and Africa, Americas and Other and Asia Pacific.
Stock Forecast FAQ
In the current month, MASS has received 3 Buy ratings 1 Hold ratings, and 0 Sell ratings. The MASS average analyst price target in the past 3 months is $6.00.
-
Where Will 908 Devices Stock Be In 1 Year?
According to analysts, the consensus estimate is that 908 Devices share price will rise to $6.00 per share over the next 12 months.
-
What Do Analysts Say About 908 Devices?
Analysts are divided on their view about 908 Devices share price and where it will be in the next 12 months. The majority of analysts rate the stock a Buy. However, a smaller subset of analysts suggest that 908 Devices is a Sell and believe this share price will drop from its current level to $6.00.
-
What Is 908 Devices's Price Target?
The price target for 908 Devices over the next 1-year time period is forecast to be $6.00 according to 4 Wall Street analysts, 3 of them rate the stock a Buy, 0 rate the stock a Sell, and 1 analyst rates the stock a Hold.
-
Is MASS A Buy, Sell Or Hold?
According to Wall Street analysts, the consensus rating for 908 Devices is a Buy. 3 of 4 analysts rate the stock a Buy at this time.
-
How Can I Buy Shares Of MASS?
You can purchase shares of 908 Devices via an online brokerage firm such as TD Ameritrade.com, thinkorswim.com, e-trade.com, tastytrade.com, or Schwab.com. Many other digital online brokerages exist such as RobinHood and Webull where you can purchase 908 Devices shares.
-
What Is The 908 Devices Share Price Today?
908 Devices was last trading at $4.30 per share. This represents the most recent stock quote for 908 Devices. Yesterday, 908 Devices closed at $4.59 per share.
-
How To Buy 908 Devices Stock Online?
In order to purchase 908 Devices stock online, open a brokerage account, deposit funds into the account, and select an order type to purchase shares whether it be market or limit.
SEE THE 1% OF STOCKS YOU NEED TO OWN FOR MASSIVE RETURNS
GET BETTER TRADE IDEAS
Popular
Is the Market Going to Go Lower?
The last month has been extremely difficult for the stock…
2 Dividend Stocks to Buy in a Recession
While many economists and investors initially expected 2025 to be…
Stock Ideas
Buy
53
Is AAPL Stock a Buy?
Market Cap: $3.2T
P/E Ratio: 35x
Buy
54
Is NVDA Stock a Buy?
Market Cap: $2.9T
P/E Ratio: 41x
Buy
51
Is MSFT Stock a Buy?
Market Cap: $2.9T
P/E Ratio: 33x
Alerts
Buy
52
RGC alert for Mar 18
Regencell Bioscience Holdings [RGC] is up 73.51% over the past day.
Buy
63
EXOD alert for Mar 18
Exodus Movement [EXOD] is down 3.96% over the past day.
Sell
45
MNPR alert for Mar 18
Monopar Therapeutics [MNPR] is up 0.93% over the past day.
